Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma

This study is a companion research project attached to a larger clinical trial (HCC 24-056) for people with advanced or inoperable melanoma (skin cancer). Its goal is to collect extra tumor biopsies and blood samples to understand how two different immunotherapy drug combinations change the immune environment inside tumors over time. **You may be eligible if...** - You already qualify to enroll in the linked parent study (HCC 24-056) for unresectable or metastatic melanoma - You are willing to provide 3 additional tumor biopsies and 3 additional blood draws beyond what the main study requires - You have tumor lesions that can be safely biopsied at least 3 times - You are able to understand and sign the consent form **You may NOT be eligible if...** - You do not qualify for the parent study (HCC 24-056) - Your tumors are not safely accessible for repeated biopsy Talk to your doctor to see if this trial is right for you.